Mecamylamine (Targacept).
Copyright policy )Mecamylamine (Targacept).
Targacept Inc, under license from the University of South Florida, is developing a low-dose, liquid gel capsule formulation of the nicotinic acetylcholine antagonist mecamylamine, as a potential treatment for various neuropsychiatric disorders.
- University of Vermont United States
Adult, Adolescent, Dose-Response Relationship, Drug, Substance-Related Disorders, Drug Evaluation, Preclinical, Nicotinic Antagonists, Mecamylamine, Drug Administration Schedule, Attention Deficit Disorder with Hyperactivity, Animals, Humans, Smoking Cessation, Child, Randomized Controlled Trials as Topic, Tourette Syndrome
Adult, Adolescent, Dose-Response Relationship, Drug, Substance-Related Disorders, Drug Evaluation, Preclinical, Nicotinic Antagonists, Mecamylamine, Drug Administration Schedule, Attention Deficit Disorder with Hyperactivity, Animals, Humans, Smoking Cessation, Child, Randomized Controlled Trials as Topic, Tourette Syndrome
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).7 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!